share_log

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Rommel Christian

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Rommel Christian

CRISPR Therapeutics | 3：首次持股聲明-董事 Rommel Christian
美股sec公告 ·  05/31 04:34
牛牛AI助理已提取核心訊息
Christian Rommel, a director and 10% owner of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 30, 2024. The Form 3 filing, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, indicates that Rommel does not beneficially own any non-derivative or derivative securities of the company. The form was filed as an individual rather than a joint/group filing and includes Rommel's signature and the date of filing.
Christian Rommel, a director and 10% owner of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 30, 2024. The Form 3 filing, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, indicates that Rommel does not beneficially own any non-derivative or derivative securities of the company. The form was filed as an individual rather than a joint/group filing and includes Rommel's signature and the date of filing.
CRISPR Therapeutics的董事兼10％所有者克里斯蒂安·****於2024年5月30日向美國證券交易委員會提交了初步的證券實益擁有權聲明。表格3申報是1934年《證券交易法》第16（a）條的要求，表明****不以實益方式擁有公司的任何非衍生或衍生證券。該表格是作爲個人而不是聯合/團體文件提交的，包括****的簽名和提交日期。
CRISPR Therapeutics的董事兼10％所有者克里斯蒂安·****於2024年5月30日向美國證券交易委員會提交了初步的證券實益擁有權聲明。表格3申報是1934年《證券交易法》第16（a）條的要求，表明****不以實益方式擁有公司的任何非衍生或衍生證券。該表格是作爲個人而不是聯合/團體文件提交的，包括****的簽名和提交日期。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。